Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BBIO)

Tipranks - Tipranks - Wed May 13, 11:56AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BBIO) with bullish sentiments.

Claim 55% Off TipRanks

Cardiol Therapeutics (CRDL)

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Cardiol Therapeutics, with a price target of $9.00. The company’s shares closed last Tuesday at $1.31.

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 2.0% and a 42.1% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Rani Therapeutics Holdings, and Connect Biopharma Holdings. ;'>

Cardiol Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.50, representing a 539.1% upside. In a report issued on May 5, Canaccord Genuity also maintained a Buy rating on the stock with a $8.00 price target.

See the top stocks recommended by analysts >>

BridgeBio Pharma (BBIO)

In a report released today, Myles Minter from William Blair reiterated a Buy rating on BridgeBio Pharma. The company’s shares closed last Tuesday at $64.80.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 34.2% and a 59.5% success rate. Minter covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, CAMP4 Therapeutics Corporation, and Neumora Therapeutics, Inc. ;'>

BridgeBio Pharma has an analyst consensus of Strong Buy, with a price target consensus of $109.27, implying a 68.3% upside from current levels. In a report issued on April 28, Barclays also maintained a Buy rating on the stock with a $157.00 price target.

Read More on CRDL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).